ClearPoint Neuro (CLPT) Competitors $12.16 -0.63 (-4.93%) Closing price 04:00 PM EasternExtended Trading$12.28 +0.12 (+0.95%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLPT vs. LQDA, CDRE, AORT, KMTS, PLSE, FNA, BLFS, ESTA, MDXG, and INMDShould you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Liquidia (LQDA), Cadre (CDRE), Artivion (AORT), Kestra Medical Technologies (KMTS), Pulse Biosciences (PLSE), Paragon 28 (FNA), BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), and InMode (INMD). These companies are all part of the "medical equipment" industry. ClearPoint Neuro vs. Liquidia Cadre Artivion Kestra Medical Technologies Pulse Biosciences Paragon 28 BioLife Solutions Establishment Labs MiMedx Group InMode ClearPoint Neuro (NASDAQ:CLPT) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment. Do analysts rate CLPT or LQDA? ClearPoint Neuro currently has a consensus price target of $25.00, indicating a potential upside of 105.59%. Liquidia has a consensus price target of $25.56, indicating a potential upside of 53.39%. Given ClearPoint Neuro's higher probable upside, equities analysts clearly believe ClearPoint Neuro is more favorable than Liquidia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ClearPoint Neuro 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Liquidia 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CLPT or LQDA? Liquidia received 188 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 89.29% of users gave ClearPoint Neuro an outperform vote while only 69.16% of users gave Liquidia an outperform vote. CompanyUnderperformOutperformClearPoint NeuroOutperform Votes2589.29% Underperform Votes310.71%LiquidiaOutperform Votes21369.16% Underperform Votes9530.84% Which has higher earnings and valuation, CLPT or LQDA? ClearPoint Neuro has higher revenue and earnings than Liquidia. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearPoint Neuro$31.39M10.84-$22.09M-$0.76-16.00Liquidia$14.14M100.69-$78.50M-$1.58-10.54 Which has more risk and volatility, CLPT or LQDA? ClearPoint Neuro has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Is CLPT or LQDA more profitable? ClearPoint Neuro has a net margin of -59.64% compared to Liquidia's net margin of -765.38%. ClearPoint Neuro's return on equity of -62.10% beat Liquidia's return on equity.Company Net Margins Return on Equity Return on Assets ClearPoint Neuro-59.64% -62.10% -38.39% Liquidia -765.38%-163.21%-67.14% Do institutionals and insiders hold more shares of CLPT or LQDA? 30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 7.0% of ClearPoint Neuro shares are held by insiders. Comparatively, 26.5% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to CLPT or LQDA? In the previous week, Liquidia had 8 more articles in the media than ClearPoint Neuro. MarketBeat recorded 18 mentions for Liquidia and 10 mentions for ClearPoint Neuro. Liquidia's average media sentiment score of 0.74 beat ClearPoint Neuro's score of 0.30 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryClearPoint Neuro and Liquidia tied by winning 9 of the 18 factors compared between the two stocks. Get ClearPoint Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLPT vs. The Competition Export to ExcelMetricClearPoint NeuroSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$340.35M$4.47B$5.35B$8.38BDividend YieldN/A43.64%5.22%4.10%P/E Ratio-17.6229.4326.8419.71Price / Sales10.8467.72391.39116.98Price / CashN/A51.0838.2534.62Price / Book14.146.236.794.50Net Income-$22.09M$68.16M$3.23B$248.18M7 Day Performance-2.17%18.33%4.07%1.14%1 Month Performance1.76%23.04%12.52%15.20%1 Year Performance100.33%20.61%16.83%6.56% ClearPoint Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLPTClearPoint Neuro1.7502 of 5 stars$12.16-4.9%$25.00+105.6%+108.6%$340.35M$31.39M-17.62110Positive NewsGap UpLQDALiquidia3.3422 of 5 stars$17.03-9.8%$25.56+50.1%+27.5%$1.46B$14.14M-10.4550News CoverageAnalyst DowngradeGap DownHigh Trading VolumeCDRECadre3.478 of 5 stars$35.31+0.1%$37.00+4.8%+12.0%$1.44B$559.81M42.542,240AORTArtivion2.4141 of 5 stars$29.61+0.3%$31.40+6.0%+22.2%$1.26B$390.08M-1,480.501,300Insider TradeKMTSKestra Medical TechnologiesN/A$24.24-1.5%$27.50+13.4%N/A$1.24B$52.64M0.00300PLSEPulse Biosciences0.9277 of 5 stars$17.13-0.3%N/A+99.0%$1.15B$700,000.000.00140Positive NewsFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+75.0%$1.10B$256.18M-17.71343,000High Trading VolumeBLFSBioLife Solutions2.4254 of 5 stars$22.94-2.8%$31.17+35.9%+4.5%$1.09B$87.76M-21.64440News CoveragePositive NewsAnalyst DowngradeESTAEstablishment Labs2.8867 of 5 stars$36.82+1.8%$55.33+50.3%-30.3%$1.06B$170.24M-14.27960Positive NewsMDXGMiMedx Group3.9581 of 5 stars$7.16+1.6%$12.50+74.6%-10.4%$1.06B$352.38M13.02870Positive NewsINMDInMode3.5073 of 5 stars$14.53-1.0%$18.54+27.6%-22.3%$1.01B$392.41M6.18480Positive News Related Companies and Tools Related Companies Liquidia Competitors Cadre Competitors Artivion Competitors Kestra Medical Technologies Competitors Pulse Biosciences Competitors Paragon 28 Competitors BioLife Solutions Competitors Establishment Labs Competitors MiMedx Group Competitors InMode Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLPT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
